The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism

An Antidiabetic Thiazolidinedione Is a High Affinity Ligand for Peroxisome Proliferator-activated Receptor γ (PPARγ)

Lehmann, J. M., Moore, L. B., Smith-Oliver, T. A., Wilkison, W. O., Willson, T. M., & Kliewer, S. A. (1995) · Journal of Biological Chemistry · doi:10.1074/jbc.270.22.12953 · Cited by 3,626 · see citing works

Atherogenesis: a postprandial phenomenon.

Zilversmit, D. B. (1979) · Circulation · doi:10.1161/01.cir.60.3.473 · Cited by 1,701 · see citing works

Effects of rimonabant on metabolic risk factors in overweight patients with dyslipidemia

Després, J.-P., Golay, A., & Sjöström, L. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa044537 · Cited by 1,392 · see citing works

Efficacy of Metformin in Patients with Non-Insulin-Dependent Diabetes Mellitus

DeFronzo, R. A., & Goodman, A. M. (1995) · New England Journal of Medicine · doi:10.1056/nejm199508313330902 · Cited by 1,368 · see citing works

Effects of exenatide (Exendin-4) on glycemic control over 30 weeks in sulfonylurea-treated patients with type 2 diabetes

Buse, J. B., Henry, R. R., Han, J., Kim, D. D., Fineman, M. S., Baron, A. D., & for the Exenatide-113 Clinical Study Group (2004) · Diabetes Care · doi:10.2337/diacare.27.11.2628 · Cited by 1,346 · see citing works

Randomised placebo-controlled trial of orlistat for weight loss and prevention of weight regain in obese patients.

Sjöström, L., Rissanen, A., Andersen, T., Boldrin, M., Golay, A., Koppeschaar, H. P., & Krempf, M. (1998) · The Lancet · doi:10.1016/s0140-6736(97)11509-4 · Cited by 1,237 · see citing works

Effect of Rimonabant, a Cannabinoid-1 Receptor Blocker, on Weight and Cardiometabolic Risk Factors in Overweight or Obese Patients

Pi-Sunyer, X., Aronne, L. J., Heshmati, H. M., Devin, J., Rosenstock, J., & for the RIO-North America Study Group (2006) · JAMA · doi:10.1001/jama.295.7.761 · Cited by 1,209 · see citing works

Relation of triglyceride metabolism and coronary artery disease. Studies in the postprandial state

Patsch, J. R., Miesenböck, G., Hopferwieser, T., Mühlberger, V, Knapp, E., Dunn, J. K., Gotto, A. M., & Patsch, W. (1992) · Arteriosclerosis and Thrombosis: A Journal of Vascular Biology · doi:10.1161/01.atv.12.11.1336 · Cited by 1,122 · see citing works

Metformin: An Update

Kirpichnikov, D., McFarlane, S. I., & Sowers, J. R. (2002) · Annals of Internal Medicine · doi:10.7326/0003-4819-137-1-200207020-00009 · Cited by 1,084 · see citing works

Lipoprotein lipase: structure, function, regulation, and role in disease

Mead, J. R., Irvine, S. A., & Ramji, D. P. (2002) · Journal of Molecular Medicine · doi:10.1007/s00109-002-0384-9 · Cited by 929 · see citing works

Antidiabetogenic effect of glucagon-like peptide-1 (7–36)amide in normal subjects and patients with diabetes mellitus

Gutniak, M., Ørkov, C., Holst, J. J., Ahrén, B., & Efendić, S. (1992) · New England Journal of Medicine · doi:10.1056/nejm199205143262003 · Cited by 868 · see citing works

Efficacy and Metabolic Effects of Metformin and Troglitazone in Type II Diabetes Mellitus

Inzucchi, S. E., Maggs, D. G., Spollett, G. R., Page, S. L., Rife, F. S., Walton, V., & Shulman, G. I. (1998) · New England Journal of Medicine · doi:10.1056/nejm199803263381303 · Cited by 794 · see citing works

Drug treatments for obesity: orlistat, sibutramine, and rimonabant

Padwal, R. S., & Majumdar, S. R. (2007) · The Lancet · doi:10.1016/s0140-6736(07)60033-6 · Cited by 753 · see citing works

Inhibition of Dipeptidyl Peptidase-4 Reduces Glycemia, Sustains Insulin Levels, and Reduces Glucagon Levels in Type 2 Diabetes

Åhrén, B., Landin‐Olsson, M., Jansson, P., Svensson, M. K. E., Holmes, D., & Schweizer, A. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031907 · Cited by 710 · see citing works

Role of orlistat in the treatment of obese patients with type 2 diabetes. A 1-year randomized double-blind study

Hollander, P. A., Elbein, S. C., Hirsch, I. B., Kelley, D., McGill, J., Taylor, T., Weiss, S. R., Crockett, S. E., Kaplan, R. A., Comstock, J., et al. (1998) · Diabetes Care · doi:10.2337/diacare.21.8.1288 · Cited by 654 · see citing works

Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group.

Aronoff, S., Rosenblatt, S., Braithwaite, S. S., Egan, J. W., Mathisen, A. L., & Schneider, R. (2000) · Diabetes Care · doi:10.2337/diacare.23.11.1605 · Cited by 626 · see citing works

Biguanides and NIDDM

Bailey, C. J. (1992) · Diabetes Care · doi:10.2337/diacare.15.6.755 · Cited by 593 · see citing works

Orlistat, a New Lipase Inhibitor for the Management of Obesity

Heck, A. M., Yanovski, J. A., & Calis, K. A. (2000) · Pharmacotherapy The Journal of Human Pharmacology and Drug Therapy · doi:10.1592/phco.20.4.270.34882 · Cited by 576 · see citing works

Interaction between free fatty acids and insulin in the acute control of very low density lipoprotein production in humans.

Lewis, G., Uffelman, K., Szeto, L., Weller, B., & Steiner, G. (1995) · Journal of Clinical Investigation · doi:10.1172/jci117633 · Cited by 533 · see citing works

Gastric emptying, glucose responses, and insulin secretion after a liquid test meal: effects of exogenous glucagon-like peptide-1 (GLP-1)-(7-36) amide in type 2 (noninsulin-dependent) diabetic patients.

Willms, B., Werner, J., Holst, J. J., Orskov, C., Creutzfeldt, W., & Nauck, M. A. (1996) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.81.1.8550773 · Cited by 502 · see citing works

Hepatic uptake of chylomicron remnants

Cooper, A. D. (1997) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)34932-4 · Cited by 499 · see citing works

Postprandial lipoproteins and progression of coronary atherosclerosis

Karpe, F., Steiner, G. A., Uffelman, K. D., Olivecrona, T., & Hamsten, A. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90085-x · Cited by 486 · see citing works

Glucosidase inhibition

Puls, W., Keup, U., Krause, H., Thomas, G., & Hoffmeister, F. (1977) · Die Naturwissenschaften · doi:10.1007/bf00483562 · Cited by 419 · see citing works

Improved Glycemic Control and Enhanced Insulin Sensitivity in Type 2 Diabetic Subjects Treated With Pioglitazone

Miyazaki, Y., Mahankali, A., Matsuda, M., Glass, L., Mahankali, S., Ferrannini, E., Cusi, K., Mandarino, L. J., & DeFronzo, R. A. (2001) · Diabetes Care · doi:10.2337/diacare.24.4.710 · Cited by 407 · see citing works

Normalization of glucose concentrations and deceleration of gastric emptying after solid meals during intravenous glucagon-like peptide 1 in patients with type 2 diabetes

Meier, J. J., Gallwitz, B., Salmen, S., Goetze, O., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2003) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-030049 · Cited by 369 · see citing works

Vildagliptin, a Dipeptidyl Peptidase-IV Inhibitor, Improves Model-Assessed β-Cell Function in Patients with Type 2 Diabetes

Mari, A., Sallas, W. M., He, Y. L., Watson, C., Ligueros-Saylan, M., Dunning, B. E., Deacon, C. F., Holst, J. J., & Foley, J. E. (2005) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2004-2460 · Cited by 361 · see citing works

Postprandial lipoprotein metabolism and atherosclerosis.

Karpe, F. (1999) · Journal of Internal Medicine · doi:10.1046/j.1365-2796.1999.00548.x · Cited by 360 · see citing works

Continuous subcutaneous infusion of glucagon-like peptide 1 lowers plasma glucose and reduces appetite in type 2 diabetic patients.

Toft-Nielsen, M.-B., Madsbad, S., & Holst, J. J. (1999) · Diabetes Care · doi:10.2337/diacare.22.7.1137 · Cited by 339 · see citing works

Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes

Matikainen, N., Mänttäri, S., Schweizer, A., Ulvestad, A., Mills, D., Dunning, B. E., Foley, J. E., & Taskinen, M.-R. (2006) · Diabetologia · doi:10.1007/s00125-006-0340-2 · Cited by 336 · see citing works

Effects of Acute Hyperinsulinemia on VLDL Triglyceride and VLDL ApoB Production in Normal Weight and Obese Individuals

Lewis, G. F., Uffelman, K. D., Szeto, L., & Steiner, G. A. (1993) · Diabetes · doi:10.2337/diab.42.6.833 · Cited by 323 · see citing works

Glucagon-like peptide-1, a new hormone of the entero-insular axis

Ørskov, C. (1992) · Diabetologia · doi:10.1007/bf00429088 · Cited by 294 · see citing works

PPARγ and the Treatment of Insulin Resistance

Olefsky, J. M., & Saltiel, A. R. (2000) · Trends in Endocrinology and Metabolism · doi:10.1016/s1043-2760(00)00306-4 · Cited by 280 · see citing works

Thiazolidinediones in Type 2 Diabetes Mellitus

Diamant, M., & Heine, R. J. (2003) · Drugs · doi:10.2165/00003495-200363130-00004 · Cited by 278 · see citing works

Glucagon-like peptide 1 abolishes the postprandial rise in triglyceride concentrations and lowers levels of non-esterified fatty acids in humans

Meier, J. J., Gethmann, A., Götze, O., Gallwitz, B., Holst, J. J., Schmidt, W. E., & Nauck, M. A. (2006) · Diabetologia · doi:10.1007/s00125-005-0126-y · Cited by 276 · see citing works

Comparison of Vildagliptin and Rosiglitazone Monotherapy in Patients With Type 2 Diabetes

Rosenstock, J., Baron, M. A., Dejager, S., Mills, D., & Schweizer, A. (2007) · Diabetes Care · doi:10.2337/dc06-1815 · Cited by 270 · see citing works

Addition of low‐dose rosiglitazone to sulphonylurea therapy improves glycaemic control in Type 2 diabetic patients

Wolffenbuttel, B. H. R., Gomis, R., Squatrito, S., Jones, N. P., & Patwardhan, R. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00224.x · Cited by 263 · see citing works

Effect of Metformin on Carbohydrate and Lipoprotein Metabolism in NIDDM Patients

Wu, M. ‐., Johnston, P., Sheu, W. H., Hollenbeck, C. B., Jeng, C., Goldfine, I. D., Chen, Y. D., & Reaven, G. M. (1990) · Diabetes Care · doi:10.2337/diacare.13.1.1 · Cited by 257 · see citing works

Insulinotropic meglitinide analogues

Dornhorst, A. (2001) · The Lancet · doi:10.1016/s0140-6736(01)06715-0 · Cited by 229 · see citing works

Sibutramine

McNeely, W., & Goa, K. L. (1998) · Drugs · doi:10.2165/00003495-199856060-00019 · Cited by 219 · see citing works

Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes

Raskin, P., Rappaport, E. B., Cole, S. T., Yan, Y., Patwardhan, R., & Freed, M. I. (2000) · Diabetologia · doi:10.1007/s001250050045 · Cited by 214 · see citing works

Metformin Improves Glucose, Lipid Metabolism, and Reduces Blood Pressure in Hypertensive, Obese Women

Giugliano, D., De Rosa, N., Di Maro, G., Marfella, R., Acampora, R., Buoninconti, R., & D'Onofrio, F. (1993) · Diabetes Care · doi:10.2337/diacare.16.10.1387 · Cited by 206 · cited 1× · see citing works

Lipoprotein abnormalities and their consequences for patients with type 2 diabetes

Krentz, A. J. (2003) · Diabetes Obesity and Metabolism · doi:10.1046/j.1462-8902.2003.0310.x · Cited by 205 · see citing works

Effects of the PPARγ agonist pioglitazone on lipoprotein metabolism in patients with type 2 diabetes mellitus

Nagashima, K., Lopez, C., Donovan, D., Ngai, C., Fontanez, N., Bensadoun, A., Fruchart-Najib, J., Holleran, S., Cohn, J. S., Ramakrishnan, R., et al. (2005) · Journal of Clinical Investigation · doi:10.1172/jci200523219 · Cited by 201 · see citing works

Insulin therapy induces antiatherogenic changes of serum lipoproteins in noninsulin-dependent diabetes.

Taskinen, M., Kuusi, T., Helve, E., Nikkilä, E. A., & Yki‐Järvinen, H. (1988) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.8.2.168 · Cited by 184 · see citing works

Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve‐week, randomized, placebo‐controlled study

Patel, J., Anderson, R. J., & Rappaport, E. B. (1999) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.1999.00020.x · Cited by 180 · see citing works

Therapeutic Potentials of Acarbose as First-Line Drug in NIDDM Insufficiently Treated With Diet Alone

Hanefeld, M., Fischer, S., Schulze, J., Spengler, M., Wargenau, M., Schollberg, K., & Fücker, K. (1991) · Diabetes Care · doi:10.2337/diacare.14.8.732 · Cited by 178 · see citing works

Metabolic Basis of Hypotriglyceridemic Effects of Insulin in Normal Men

Malmström, R., Packard, C. J., Watson, T. D. G., Rannikko, S., CASLAKE, M. J., Bedford, D. K., Stewart, P., Yki‐Järvinen, H., Shepherd, J., & Taskinen, M. (1997) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.17.7.1454 · Cited by 178 · see citing works

Thiazolidinediones and Blood Lipids in Type 2 Diabetes

van Wijk, J. P. H., de Koning, E. J. P., Martens, E. P., & Rabelink, T. J. (2003) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/01.atv.0000090521.25968.4d · Cited by 164 · see citing works

Postprandial lipemia and cardiovascular disease

Hyson, D. A., Rutledge, J. C., & Berglund, L. (2003) · Current Atherosclerosis Reports · doi:10.1007/s11883-003-0033-y · Cited by 160 · see citing works

Effects of NIDDM on Very-Low-Density Lipoprotein Triglyceride and Apolipoprotein B Metabolism: Studies Before and After Sulfonylurea Therapy

Taskinen, M., Beltz, W. F., Harper, I., Fields, R. M., Schonfeld, G., Grundy, S. M., & Howard, B. V. (1986) · Diabetes · doi:10.2337/diab.35.11.1268 · Cited by 159 · see citing works

Detection, quantification, and characterization of potentially atherogenic triglyceride-rich remnant lipoproteins

Cohn, J. S., Marcoux, C., & Davignon, J. (1999) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/01.atv.19.10.2474 · Cited by 156 · see citing works

Triglyceride-Rich Lipoprotein Remnant Particles and Risk of Atherosclerosis

Hodis, H. N. (1999) · Circulation · doi:10.1161/01.cir.99.22.2852 · Cited by 149 · see citing works

Subcutaneous Injection of the Incretin Hormone Glucagon-Like Peptide 1 Abolishes Postprandial Glycemia in NIDDM

Gutniak, M., Linde, B., Holst, J. J., & Efendić, S. (1994) · Diabetes Care · doi:10.2337/diacare.17.9.1039 · Cited by 139 · see citing works

Importance of Early Insulin Secretion

Hollander, P. A., Schwartz, S. L., Gatlin, M. R., Haas, S. J., Zheng, H., Foley, J. E., & Dunning, B. E. (2001) · Diabetes Care · doi:10.2337/diacare.24.6.983 · Cited by 131 · see citing works

The effects of oral anti‐hyperglycaemic medications on serum lipid profiles in patients with type 2 diabetes

Buse, J. B., Tan, M. H., PRINCE, M. J., & Erickson, P. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00325.x · Cited by 129 · see citing works

A 1-year multicenter randomized double-blind comparison of repaglinide and glyburide for the treatment of type 2 diabetes. Dutch and German Repaglinide Study Group.

Wolffenbuttel, B. H. R., & Landgraf, R. (1999) · Diabetes Care · doi:10.2337/diacare.22.3.463 · Cited by 129 · see citing works

Triglyceride‐rich lipoproteins in non‐insulin‐dependent diabetes mellitus: post‐prandial metabolism and relation to premature atherosclerosis

de Man, F. H. A. F., Cabezas, M. C., van Barlingen, H. H. J. J., Erkelens, D. W., & de Bruin, T. W. (1996) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.1996.114256.x · Cited by 124 · see citing works

Effect of Metformin on Postprandial Lipemia in Patients With Fairly to Poorly Controlled NIDDM

Jeppesen, J., Zhou, M., Chen, Y. I., & Reaven, G. M. (1994) · Diabetes Care · doi:10.2337/diacare.17.10.1093 · Cited by 119 · see citing works

The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes

Tan, G. D., Fielding, B. A., Currie, J. M., Humphreys, S. M., D�sage, M., Frayn, K. N., Laville, M., Vidal, H., & Karpe, F. (2004) · Diabetologia · doi:10.1007/s00125-004-1619-9 · Cited by 119 · see citing works

Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus

Nolan, J. J., Jones, N. P., Patwardhan, R., & Deacon, L. F. (2000) · Diabetic Medicine · doi:10.1046/j.1464-5491.2000.00269.x · Cited by 116 · see citing works

Fasting and postprandial determinants for the occurrence of small dense LDL species in non-insulin-dependent diabetic patients with and without hypertriglyceridaemia: the involvement of insulin, insulin precursor species and insulin resistance

Tan, K. C. B., Cooper, M. B., Ling, K. L. E., Griffin, B. A., Freeman, D. J., Packard, C. J., Shepherd, J., Hales, C. N., & Betteridge, D. J. (1995) · Atherosclerosis · doi:10.1016/0021-9150(94)05454-q · Cited by 110 · see citing works

Effect of Sibutramine on Weight Management and Metabolic Control in Type 2 Diabetes

Vettor, R., Serra, R., Fabris, R., Pagano, C., & Federspil, G. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.942 · Cited by 105 · see citing works

Exogenous and Endogenous Postprandial Lipid Abnormalities in Type 2 Diabetic Patients with Optimal Blood Glucose Control and Optimal Fasting Triglyceride Levels

Rivellese, A. A., Natale, C. D., Marino, L. D., Patti, L., Iovine, C., Coppola, S., Prato, S. D., Riccardi, G., & Annuzzi, G. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031764 · Cited by 100 · see citing works

Combined metformin-sulfonylurea treatment of patients with noninsulin- dependent diabetes in fair to poor glycemic control

Reaven, G. M., Johnston, P., Hollenbeck, C. B., Skowroński, R., Zhang, J. C., Goldfine, I. D., & Chen, Y. I. (1992) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jcem.74.5.1569149 · Cited by 96 · see citing works

Lipoprotein lipase and its role in regulation of plasma lipoproteins and cardiac risk

Otarod, J. K., & Goldberg, I. J. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0043-4 · Cited by 88 · see citing works

Acute Hyperinsulinism Modulates Plasma Apolipoprotein B-48 Triglyceride--Rich Lipoproteins in Healthy Subjects During the Postprandial Period

Harbis, A., Defoort, C., Narbonne, H., Juhel, C., Senft, M., Latge, C., Delenne, B., Portugal, H., Atlan-Gepner, C., Vialettes, B., et al. (2001) · Diabetes · doi:10.2337/diabetes.50.2.462 · Cited by 87 · see citing works

A review of the metabolic effects of sibutramine

Filippatos, T. D., Kiortsis, D. N., Liberopoulos, E. N., Mikhailidis, D. P., & Elisaf, M. (2005) · Current Medical Research and Opinion · doi:10.1185/030079905x38132 · Cited by 85 · see citing works

Effect of Acarbose on Carbohydrate and Lipid Metabolism in NIDDM Patients Poorly Controlled by Sulfonylureas

Reaven, G. M., Lardinois, C. K., Greenfield, M. S., Schwartz, H. C., & Vreman, H. J. (1990) · Diabetes Care · doi:10.2337/diacare.13.3.32 · Cited by 84 · see citing works

Rosiglitazone Improves Postprandial Triglyceride and Free Fatty Acid Metabolism in Type 2 Diabetes

van Wijk, J. P. H., de Koning, E. J. P., Cabezas, M. C., & Rabelink, T. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.844 · Cited by 82 · see citing works

Studies on the antiobesity activity of tetrahydrolipstatin, a potent and selective inhibitor of pancreatic lipase.

Hogan, S. L., Fleury, A., Hadváry, P., Lengsfeld, H., Meier, M. K., Triscari, J. M., & Sullivan, A. C. (1987) · PubMed · Cited by 81 · see citing works

Acute Hyperinsulinemia Decreases the Hepatic Secretion of Very-Low-Density Lipoprotein Apolipoprotein B-100 in NIDDM

Cummings, M. H., Watts, G. F., Umpleby, A. M., Hennessy, T. R., Kelly, J. M., Jackson, N. C., & Sönksen, P. H. (1995) · Diabetes · doi:10.2337/diab.44.9.1059 · Cited by 74 · see citing works

Postprandial lipemia: An under-recognized atherogenic factor in patients with diabetes mellitus

Pastromas, S. C., Terzi, A. B., Tousoulis, D., & Koulouris, S. N. (2007) · International Journal of Cardiology · doi:10.1016/j.ijcard.2007.04.172 · Cited by 69 · see citing works

How does sibutramine work?

Lean, M. (2001) · International Journal of Obesity · doi:10.1038/sj.ijo.0801931 · Cited by 68 · see citing works

Lipid Metabolism in Non-Insulin-Dependent Diabetes Mellitus

Greenfield, M. S. (1982) · Archives of Internal Medicine · doi:10.1001/archinte.142.8.1498 · Cited by 66 · see citing works

The Antidiabetogenic Effect of GLP-1 Is Maintained During a 7-Day Treatment Period and Improves Diabetic Dyslipoproteinemia in NIDDM Patients

Juntti‐Berggren, L., Pigon, J., Karpe, F., Hamsten, A., Gutniak, M., Vignati, L., & Efendić, S. (1996) · Diabetes Care · doi:10.2337/diacare.19.11.1200 · Cited by 63 · see citing works

LDL-cholesterol, HDL-cholesterol or triglycerides—which is the culprit?

Taskinen, M. (2003) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(03)00126-8 · Cited by 62 · see citing works

Relationship between improved postprandial lipemia and low-density lipoprotein metabolism during treatment with tetrahydrolipstatin, a pancreatic lipase inhibitor

Reitsma, J. B., Cabezas, M. C., de Bruin, T. W., & Erkelens, D. W. (1994) · Metabolism · doi:10.1016/0026-0495(94)90095-7 · Cited by 60 · see citing works

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

Kado, S., Murakami, T., Aoki, A., Nagase, T., Katsura, Y., Noritake, M., Matsuoka, T., & Nagata, N. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00062-x · Cited by 59 · see citing works

Effects of insulin lispro and chronic vitamin C therapy on postprandial lipaemia, oxidative stress and endothelial function in patients with type 2 diabetes mellitus

Evans, M., Anderson, R., Smith, J. C., Khan, N., Graham, J. M., Thomas, A. W., Morris, K., Deely, D., Frenneaux, M. P., Davies, J. S., et al. (2003) · European Journal of Clinical Investigation · doi:10.1046/j.1365-2362.2003.01120.x · Cited by 59 · see citing works

The effects of theα-glucosidase inhibitor BAY g 5421 (Acarbose) on postprandial blood glucose, serum insulin, and triglyceride levels: Dose-time-response relationships in man

Hillebrand, I., Boehme, K., Frank, G., Fink, H., & Berchtold, P. (1979) · Research in Experimental Medicine · doi:10.1007/bf01851237 · Cited by 58 · see citing works

The effect of sensitisation to insulin with pioglitazone on fasting and postprandial lipid metabolism, lipoprotein modification by lipases, and lipid transfer activities in type 2 diabetic patients

Majali, K. A., Cooper, M. B., Staels, B., Luc, G., Taskinen, M., & Betteridge, D. J. (2006) · Diabetologia · doi:10.1007/s00125-005-0092-4 · Cited by 58 · see citing works

Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study

Chappuis, B., Braun, M., Stettler, C., Allemann, S., Diem, P., Lumb, P. J., Wierzbicki, A. S., James, R. W., & Christ, E. (2007) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.715 · Cited by 54 · see citing works

Acarbose lowers serum triglyceride and postprandial chylomicron levels in type 2 diabetes

Ogawa, S., Takeuchi, K., & Ito, S. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1462-8902.2004.00362.x · Cited by 52 · see citing works

Insulin and non-esterified fatty acid relations to alimentary lipaemia and plasma concentrations of postprandial triglyceride-rich lipoproteins in healthy middle-aged men

Boquist, S., Hamsten, A., Karpe, F., & Ruotolo, G. (2000) · Diabetologia · doi:10.1007/s001250050028 · Cited by 50 · see citing works

Effects of nateglinide and glibenclamide on postprandial lipid and glucose metabolism in type 2 diabetes

Vakkilainen, J., Mero, N., Schweizer, A., Foley, J. E., & Taskinen, M. (2002) · Diabetes/Metabolism Research and Reviews · doi:10.1002/dmrr.324 · Cited by 50 · see citing works

Postprandial lipemia—effect of lipid-lowering drugs

Karpe, F. (2002) · Atherosclerosis Supplements · doi:10.1016/s1567-5688(01)00004-6 · Cited by 50 · see citing works

Treatment of hypertriglyceridemia with metformin

Sirtori, C. R., Tremoli, E., Sirtori, M., Conti, F., & Paoletti, R. (1977) · Atherosclerosis · doi:10.1016/0021-9150(77)90125-3 · Cited by 48 · see citing works

Efficacy of α‐glucosidase inhibitors on lipids in NIDDM subjects with moderate hyperlipidaemia

Leonhardt, W., Markolf Hanefeld, E., Fischer, S., & Schulze, J. (1994) · European Journal of Clinical Investigation · doi:10.1111/j.1365-2362.1994.tb02256.x · Cited by 43 · see citing works

Effects of CB1 antagonist on the control of metabolic functions in obese type 2 diabetic patients

Lafontan, M., Piazza, P. V., & Girard, J. R. (2007) · Diabetes & Metabolism · doi:10.1016/j.diabet.2007.02.001 · Cited by 42 · see citing works

Acute effect of orlistat on post‐prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus

Tan, K. C. B., Tso, A. W. K., Tam, S., Pang, R. W. C., & Lam, K. S. L. (2002) · Diabetic Medicine · doi:10.1046/j.1464-5491.2002.00823.x · Cited by 41 · see citing works

Pyridine nucleotides in glucose metabolism and diabetes: a review

Wahlberg, G., Adamson, U., & Svensson, J. (2000) · Diabetes/Metabolism Research and Reviews · doi:10.1002/(sici)1520-7560(200001/02)16:1 · Cited by 40 · see citing works

The effect of metformin and rosiglitazone on postprandial lipid metabolism in obese insulin‐resistant subjects

James, A. P., Watts, G. F., & Mamo, J. C. L. (2004) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2004.00407.x · Cited by 40 · see citing works

The effect of short-term α-glucosidase inhibition on carbohydrate and lipid metabolism in type II (noninsulin-dependent) diabetics

Baron, A., Eckel, R. H., Schmeiser, L., & Kolterman, O. (1987) · Metabolism · doi:10.1016/0026-0495(87)90035-7 · Cited by 38 · see citing works

Treatment of Diabetic Dyslipoproteinemia

Steinmetz, A. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-41748 · Cited by 34 · see citing works

Will acarbose improve the metabolic abnormalities of insulin-resistant type 2 diabetes mellitus?

Scott, R. S., Lintott, C. J., Zimmet, P., Campbell, L. V., Bowen, K. M., & Welborn, T. A. (1999) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(99)00009-1 · Cited by 33 · see citing works

Insulin and Sulfonylurea Therapy in NIDDM Patients: Are the Effects on Lipoprotein Metabolism Different Even With Similar Blood Glucose Control?

Romano, G., Patti, L., Innelli, F., Marino, L. D., Annuzzi, G., Iavicoli, M., Coronel, G. A., Riccardi, G., & Rivellese, A. A. (1997) · Diabetes · doi:10.2337/diacare.46.10.1601 · Cited by 33 · see citing works

Effects of Pioglitazone vs Glibenclamide on Postprandial Increases in Glucose and Triglyceride Levels and on Oxidative Stress in Japanese Patients with Type 2 Diabetes

Mori, Y., Itoh, Y., Obata, T., & Tajima, N. (2006) · Endocrine · doi:10.1385/endo:29:1:143 · Cited by 29 · see citing works

Biphasic Insulin Aspart Compared to Biphasic Human Insulin Reduces Postprandial Hyperlipidemia in Patients with Type 2 Diabetes

Schmoelzer, I., Campo, A. D., Pressl, H., Stelzl, H., Dittrich, P., Oettl, K., & Wascher, T. C. (2005) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2005-837521 · Cited by 29 · see citing works

Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome

Cottrell, D. A., Marshall, B. J., & Falko, J. M. (2003) · Current Opinion in Cardiology · doi:10.1097/00001573-200307000-00010 · Cited by 29 · see citing works

Orlistat fails to alter postprandial plasma lipid excursions or plasma lipases in normal-weight male volunteers

Shepard, T., Jensen, D. R., Blotner, S. D., Zhi, J., Guerciolini, R., Pace, D. G., & Eckel, R. H. (2000) · International Journal of Obesity · doi:10.1038/sj.ijo.0801105 · Cited by 28 · see citing works

Effect of glipizide treatment on postprandial lipaemia in patients with NIDDM

Jeppesen, J., Zhou, M., Chen, Y. I., & Reaven, G. M. (1994) · Diabetologia · doi:10.1007/bf00404335 · Cited by 26 · see citing works

Effect of orlistat on postprandial lipemia, NMR lipoprotein subclass profiles and particle size

Suter, P. M., Marmier, G., Veya-Linder, C., Hänseler, E., Lentz, J. J., Vetter, W., & Otvos, J. D. (2005) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2004.11.023 · Cited by 26 · see citing works

The effect of improved post-prandial blood glucose control on post-prandial metabolism and markers of vascular risk in people with Type 2 diabetes

Gallagher, A., & Home, P. (2004) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2004.07.010 · Cited by 26 · see citing works

Hepatic lipase: Friend or foe and under what circumstances?

Jansen, H. (2004) · Current Atherosclerosis Reports · doi:10.1007/s11883-004-0044-3 · Cited by 25 · see citing works

Mechanism of action of a new class of insulin secretagogues

Malaisse, W. J. (2009) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-0029-1212170 · Cited by 24 · see citing works

Insulin improves fasting and postprandial lipemia in type 2 diabetes

Geltner, C., Lechleitner, M., Föger, B., Ritsch, A., Drexel, H., & Patsch, J. R. (2002) · European Journal of Internal Medicine · doi:10.1016/s0953-6205(02)00038-9 · Cited by 22 · see citing works

Acarbose treatment of non-insulin-dependent diabetes mellitus.

Lardinois, C. K., Greenfield, M. S., Schwartz, H. C., Vreman, H. J., & Reaven, G. M. (1984) · PubMed · Cited by 21 · see citing works

Effects of pioglitazone on fasting and postprandial levels of lipid and hemostatic variables in overweight non‐diabetic patients with coronary artery disease

Mieszczanska, H. Z., Kaba, N. K., Francis, C. W., Gerich, J. E., Dodis, R., Schwarz, K. Q., Phipps, R. P., SMITH, B. H., Lee, M. M.-S., Messing, S. P., et al. (2007) · Journal of Thrombosis and Haemostasis · doi:10.1111/j.1538-7836.2007.02442.x · Cited by 20 · see citing works

The DPP‐4 inhibitor vildagliptin: robust glycaemic control in type 2 diabetes and beyond

Panina, G. (2007) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2007.00763.x · Cited by 19 · see citing works

The Effects of Glibenclamide on Glucose Homeostasis and Lipoprotein Metabolism in Poorly Controlled Type 2 Diabetes

Baynes, C., Elkeles, R. S., Henderson, A., Richmond, W., & Johnston, D. G. (1993) · Hormone and Metabolic Research · doi:10.1055/s-2007-1002051 · Cited by 19 · see citing works

Premeal insulin lispro plus bedtime NPH or twice-daily NPH in patients with type 2 diabetes: acute postprandial and chronic effects on glycemic control and cardiovascular risk factors

Ceriello, A., Prato, S. D., Bue‐Valleskey, J. M., Beattie, S. D., Gates, J. R., de la Peña, A., & Malone, J. K. (2006) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2005.11.005 · Cited by 18 · see citing works

Effects of fibric acid derivatives and metformin on postprandial lipemia

Weintraub, M. S., Charach, G., & Grosskopf, I. (1998) · Atherosclerosis · doi:10.1016/s0021-9150(98)00221-4 · Cited by 16 · see citing works

Glibenclamide improves postprandial hypertriglyceridaemia in Type 2 diabetic patients by reducing chylomicrons but not the very low‐density lipoprotein subfraction levels

Skrapari, I. C., Perrea, D. N., Ioannidis, I., Karabina, S., Elisaf, M., Tselepis, A. D., Karagiannacos, P., & Katsilambros, N. L. (2001) · Diabetic Medicine · doi:10.1046/j.1464-5491.2001.00538.x · Cited by 15 · see citing works

Favorable Effects of Early Insulin Secretion by Nateglinide on Postprandial Hyperlipidemia in Patients With Type 2 Diabetes

Ai, M., Tanaka, A., Ogita, K., & Shimokado, K. (2006) · Diabetes Care · doi:10.2337/dc05-2336 · Cited by 14 · see citing works

Effects of Acarbose on Serum Lipoproteins in Healthy Individuals during Prolonged Administration of a Fiber-Free Formula Diet

Walter‐Sack, I., Wolfram, G., & llner, N. Z. O. (1989) · Annals of Nutrition and Metabolism · doi:10.1159/000177527 · Cited by 14 · see citing works

Lack of Effect of Pioglitazone on Postprandial Triglyceride Levels in Type 2 Diabetes

Shimono, D., Kuwamura, N., Nakamura, Y., & Koshiyama, H. (2001) · Diabetes Care · doi:10.2337/diacare.24.5.971 · Cited by 14 · see citing works

Treatment of familial hypertriglyceridaemia with acarbose

Malaguarnera, M., Giugno, I., Ruello, P., Maugeri, D., & Pistone, G. (2000) · Diabetes Obesity and Metabolism · doi:10.1046/j.1463-1326.2000.00065.x · Cited by 14 · see citing works

Effects of glyburide therapy on lipoproteins in non-insulin-dependent diabetes mellitus

Hughes, T. A., Kramer, J., & Segrest, J. P. (1985) · The American Journal of Medicine · doi:10.1016/s0002-9343(85)80013-9 · Cited by 13 · see citing works

Acute nateglinide administration in subjects with type 2 diabetes: effects on postprandial metabolism, coagulation, and fibrinolysis

Tentolouris, N., Boutati, E. I., Karambakalis, N., Perea, D., Tselepis, A. D., Tsoukala, C. G., Kyriaki, D., Lourida, E. S., Anastasopoulou, I., Karafoullidou, A., et al. (2005) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2004.06.002 · Cited by 13 · see citing works

The effect of 1-yr sibutramine treatment on glucose tolerance, insulin sensitivity and serum lipid profiles in obese subjects.

Sabuncu, T., Uçar, E. Y., Birden, F., & Yasar, O. (2004) · PubMed · Cited by 10 · see citing works

The Effect of Short-Term Glycemic Regulation with Gliclazide and Metformin on Postprandial Lipemia

Emral, R., Köseoğluları, O., Gedik, V. T., Uysal, A., Kamel, N., & Çorapçıoğlu, D. (2005) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2004-830536 · Cited by 9 · see citing works

Lack of Effect of Acute Repaglinide Administration on Postprandial Lipaemia in Patients with Type 2 Diabetes Mellitus

Tentolouris, N., Kolia, M., Tselepis, A. D., Perea, D., Kitsou, E., Kyriaki, D., Tambaki, A. P., Karabina, S., Sala, C., Fragoulopoulos, E., et al. (2003) · Experimental and Clinical Endocrinology & Diabetes · doi:10.1055/s-2003-42729 · Cited by 9 · see citing works

What Is the Potential Role of Cannabinoid-1 Receptor Blockade in Glucose and Lipid Management?

Jensen, M. D. (2007) · The American Journal of Medicine · doi:10.1016/j.amjmed.2007.06.011 · Cited by 8 · see citing works

The effect of nateglinide stimulated insulin secretion on post challenge glucose and lipid metabolism in Type 2 diabetes

Mohanlal, N., & Holman, R. R. (2002) · Diabetologia · Cited by 2 · see citing works

Metformin: An Old But Still the Best Treatment for Type 2 Diabetes

Rojas, L. B. A., & Gomes, M. B. (2013) · Diabetology & Metabolic Syndrome · doi:10.1186/1758-5996-5-6 · Cited by 567 · see citing works

Liraglutide suppresses postprandial triglyceride and apolipoprotein <scp>B48</scp> elevations after a fat‐rich meal in patients with type 2 diabetes: a randomized, double‐blind, placebo‐controlled, cross‐over trial

Hermansen, K., Bækdal, T. A., Düring, M., Pietraszek, A., Mortensen, L. S., Jørgensen, H., & Flint, A. (2013) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12133 · Cited by 143 · see citing works

Metformin-inclusive Therapy Reduces the Risk of Stroke in Patients with Diabetes: A 4-Year Follow-up Study

Cheng, Y., Leu, H., Chen, T., Chen, C.-L., Kuo, C., Lee, S., & Kao, C.-L. (2013) · Journal of Stroke and Cerebrovascular Diseases · doi:10.1016/j.jstrokecerebrovasdis.2013.09.001 · Cited by 104 · see citing works

Effects on Lipid Profile of Dipeptidyl Peptidase 4 Inhibitors, Pioglitazone, Acarbose, and Sulfonylureas: Meta-analysis of Placebo-Controlled Trials

Monami, M., Vitale, V., Ambrosio, M. L., Bartoli, N., Toffanello, G., Ragghianti, B., Monami, F., Marchionni, N., & Mannucci, E. (2012) · Advances in Therapy · doi:10.1007/s12325-012-0045-5 · Cited by 97 · see citing works

Neuroprotective effects of metformin against Aβ-mediated inhibition of long-term potentiation in rats fed a high-fat diet

Asadbegi, M., Yaghmaei, P., Salehi, I., Ebrahim‐Habibi, A., & Komaki‬, A. (2016) · Brain Research Bulletin · doi:10.1016/j.brainresbull.2016.02.005 · Cited by 87 · see citing works

Treatment options for the management of hypertriglyceridemia: strategies based on the best-available evidence

Maki, K. C., Bays, H. E., & Dicklin, M. R. (2012) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2012.04.003 · Cited by 83 · see citing works

Orlistat: current status in clinical therapeutics

McClendon, K. S., Riche, D. M., & Uwaifo, G. I. (2009) · Expert Opinion on Drug Safety · doi:10.1517/14740330903321485 · Cited by 84 · see citing works

From fatty-acid sensing to chylomicron synthesis: Role of intestinal lipid-binding proteins

Buttet, M., Traynard, V., Tran, T. T. T., Besnard, P., Poirier, H., & Niot, I. (2013) · Biochimie · doi:10.1016/j.biochi.2013.08.011 · Cited by 84 · see citing works

Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors

Rizzo, M., Rizvi, A. A., Spinas, G. A., Rini, G. B., & Berneis, K. K. (2009) · Expert Opinion on Investigational Drugs · doi:10.1517/14728220903241633 · Cited by 83 · see citing works

Cardiovascular impact of drugs used in the treatment of diabetes

Triggle, C. R., & Ding, H. (2014) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622314546125 · Cited by 66 · see citing works

Postprandial hypertriglyceridaemia revisited in the era of non-fasting lipid profile testing: a 2019 Expert Panel Statement, Main Text

Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez-Martínez, P., Mora, S., Bilianou, H., Panotopoulos, G., Katsiki, N., Ooi, T. C., Lopez-Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190507110519 · Cited by 61 · see citing works

Therapies for type 2 diabetes: lowering HbA1c and associated cardiovascular risk factors

Kurukulasuriya, L., & Sowers, J. (2010) · Cardiovascular Diabetology · doi:10.1186/1475-2840-9-45 · Cited by 62 · see citing works

Complications of Diabetes Therapy

Corathers, S. D., Peavie, S., & Salehi, M. (2013) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2013.06.005 · Cited by 58 · see citing works

Highly Selective Oligosaccharide Sensing by a Curdlan−Polythiophene Hybrid

Fukuhara, G., & Inoue, Y. (2010) · Journal of the American Chemical Society · doi:10.1021/ja110075p · Cited by 49 · see citing works

Pharmacological treatment options for severe hypertriglyceridemia and familial chylomicronemia syndrome

Chaudhry, R., Viljoen, A., & Wierzbicki, A. S. (2018) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2018.1480368 · Cited by 46 · see citing works

Obesogens and male fertility

Cardoso, A. M., Alves, M. G., Mathur, P. P., Oliveira, P. F., Cavaco, J. E. B., & Rato, L. (2016) · Obesity Reviews · doi:10.1111/obr.12469 · Cited by 41 · see citing works

Polymer-based supramolecular sensing and application to chiral photochemistry

Fukuhara, G. (2015) · Polymer Journal · doi:10.1038/pj.2015.52 · Cited by 38 · see citing works

Effects of insulin and other antihyperglycaemic agents on lipid profiles of patients with diabetes

Chaudhuri, A., & Dandona, P. (2011) · Diabetes Obesity and Metabolism · doi:10.1111/j.1463-1326.2011.01423.x · Cited by 28 · see citing works

Cardiovascular Implications of Antihyperglycemic Therapies for Type 2 Diabetes

Ovalle, F. (2011) · Clinical Therapeutics · doi:10.1016/j.clinthera.2011.04.006 · Cited by 27 · see citing works

Oligosaccharide sensing with chromophore-modified curdlan in aqueous media

Fukuhara, G., & Inoue, Y. (2010) · Chemical Communications · doi:10.1039/c0cc02568b · Cited by 26 · see citing works

Chylomicronemia Syndrome

Wierzbicki, A. S. (2018) · Wiley eBooks · doi:10.1002/9781119374800.ch44 · Cited by 26 · see citing works

Insulin Resistance and Triglycerides

Glueck, C. J., Khan, N., Umar, M., Uppal, M., Ahmed, W., Morrison, J. A., Goldenberg, N., & Wang, P. (2009) · Journal of Investigative Medicine · doi:10.2310/jim.0b013e3181bca9d2 · Cited by 25 · see citing works

Allosteric signal-amplification sensing with polymer-based supramolecular hosts

Fukuhara, G. (2019) · Journal of Inclusion Phenomena and Macrocyclic Chemistry · doi:10.1007/s10847-019-00881-2 · Cited by 25 · see citing works

A synthetic free fatty acid-regulated transgene switch in mammalian cells and mice

Liu, Y., Hamri, G. C., Ye, H., & Fussenegger, M. (2018) · Nucleic Acids Research · doi:10.1093/nar/gky805 · Cited by 22 · see citing works

Postprandial Hypertriglyceridaemia Revisited in the Era of Non-Fasting Lipid Profile Testing: A 2019 Expert Panel Statement, Narrative Review

Kolovou, G. D., Watts, G. F., Mikhailidis, D. P., Pérez‐Martínez, P., Mora, S., Bilianou, H. I., Panotopoulos, G., Katsiki, N., Ooi, T. C., López‐Miranda, J., et al. (2019) · Current Vascular Pharmacology · doi:10.2174/1570161117666190503123911 · Cited by 22 · see citing works

Differential modulatory effects of rosiglitazone and pioglitazone on white adipose tissue in db/db mice

Yang, K.-J., Noh, J., Kim, Y., Gang, G., Hwang, J.-H., Yang, S. J., Yeom, Y. I., & Lee, C. (2010) · Life Sciences · doi:10.1016/j.lfs.2010.08.002 · Cited by 18 · see citing works

Postprandial hyperlipidemia as a risk factor in patients with type 2 diabetes

Tomlinson, B., Chan, P., & Lam, C. W. K. (2020) · Expert Review of Endocrinology & Metabolism · doi:10.1080/17446651.2020.1750949 · Cited by 17 · see citing works

Oligosaccharide Sensing in Aqueous Media by Porphyrin–Curdlan Conjugates: A Prêt‐á‐Porter Rather Than Haute‐Couture Approach

Fukuhara, G., Sasaki, M., Numata, M., Mori, T., & Inoue, Y. (2017) · Chemistry - A European Journal · doi:10.1002/chem.201701360 · Cited by 14 · see citing works

Expansion and contraction: the mighty, mighty fatty acid

Plutzky, J. (2009) · Nature Medicine · doi:10.1038/nm0609-618 · Cited by 14 · see citing works

Oligosaccharide Sensing in Aqueous Media Using Porphyrin–Curdlan Conjugates: An Allosteric Signal-Amplification System

Sasaki, M., Ryoson, Y., Numata, M., & Fukuhara, G. (2019) · The Journal of Organic Chemistry · doi:10.1021/acs.joc.9b00040 · Cited by 13 · see citing works

Review of approved pioglitazone combinations for type 2 diabetes

Forst, T. M., Markolf Hanefeld, E., & Pfützner, A. (2011) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2011.567266 · Cited by 12 · see citing works

Smart polymer chemosensors: signal-amplification systems with allosterism

Fukuhara, G. (2021) · Polymer Journal · doi:10.1038/s41428-021-00547-2 · Cited by 9 · see citing works

Acute Effects of Metformin and Vildagliptin after a Lipid-Rich Meal on Postprandial Microvascular Reactivity in Patients with Type 2 Diabetes and Obesity: A Randomized Trial

Schiappacassa, A., Maranhao, P. A., de Souza, M. D. G. C., Panazzolo, D. G., Neto, J. F. N., Bouskela, E., & Kraemer‐Aguiar, L. G. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9103228 · Cited by 8 · see citing works

The effect of acarbose on lipid profiles in adults: a systematic review and meta-analysis of randomized clinical trials

Yousefi, M., Fateh, S. T., Nikbaf‐Shandiz, M., Gholami, F., Rastgoo, S., Bagher, R., Khadem, A., Shiraseb, F., & Asbaghi, O. (2023) · BMC Pharmacology and Toxicology · doi:10.1186/s40360-023-00706-6 · Cited by 8 · see citing works

Incretins in type 2 diabetes mellitus: cardiovascular and anti-atherogenic effects beyond glucose lowering.

Psallas, M., & Manes, C. (2012) · Europe PMC (PubMed Central) · Cited by 7 · see citing works

Getting the label in: practical research strategies for tracing dietary fat

Lambert, J. E., & Parks, E. J. (2012) · International Journal of Obesity Supplements · doi:10.1038/ijosup.2012.22 · Cited by 6 · see citing works

Oligosaccharide Sensing Using Fluorophore-Probed Curdlans in Aqueous Media

Kurohara, H., Hori, Y., Numata, M., & Fukuhara, G. (2023) · ACS Applied Polymer Materials · doi:10.1021/acsapm.2c02251 · Cited by 5 · see citing works

Metformin Use Among Individuals at Risk for Type 2 Diabetes

Kuller, L. H. (2012) · Current Diabetes Reports · doi:10.1007/s11892-012-0263-x · Cited by 4 · see citing works

Dipeptidyl Peptidase-4 Inhibitors Improved Lipid Levels in Patients With Type 2 Diabetes: A Meta-analysis of Randomized Clinical Trials

Zhao, L., Meng, J., Li, J., Cong, H., Liu, C., Yang, Y., Wu, Y., & Liu, X. (2025) · Nutrition Reviews · doi:10.1093/nutrit/nuaf209 · Cited by 3 · see citing works

Polyphenols From Mallotus peltatus (Geiseler) Mull. Arg. Ameliorates FFA‐Induced Hepatic Steatosis in L02 Cells and Reduces Lipid Accumulation in Caenorhabditis elegans

Hao, K., Zhang, Y., Li, Y., Zhong, R., Wang, X., Chang, X. M., Jiang, J., & Zhu, W. (2025) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.202400689 · Cited by 2 · see citing works

Fluorophore-Probed Curdlan Polysaccharide Chemosensor: “Turn-On” Oligosaccharide Sensing in Aqueous Media

Norikuni, M., Hori, Y., Numata, M., Matsusaki, M., Kida, T., & Fukuhara, G. (2024) · ACS Omega · doi:10.1021/acsomega.4c01786 · Cited by 1 · see citing works

THE EFFECT OF METFORMIN 0N CYTOKINES IN IRAQI PATIENTS WITH TYPE 2 DIABETES

Yasser, M. K., R, A. M., & Saba, H. (2013) · Innovare Academic Sciences Pvt Ltd - Innovare Journal of Medical Sciences · Cited by 1 · see citing works

Fluorophore-glucan conjugate for oligosaccharide sensing in aqueous media

Kurohara, H., Hori, Y., Numata, M., & Fukuhara, G. (2024) · Polymer Journal · doi:10.1038/s41428-024-00889-7 · Cited by 1 · see citing works

Diabetes management by primary health care nurses in Auckland: A cross-sectional study

Daly, B. M. (2012) · ResearchSpace (University of Auckland) · Cited by 1 · see citing works

Is darkfield microscopic examination of fresh capillary blood a valid point of care screening to assess metabolic syndrome risk factors

Reeve, K. (2015) · Cross Connect (Southern Cross University)

The influence of orlistat (Xenical) therapy on the parameters of lipid metabolism in patients with obesity

Mazurina, N. V., & Masurina, N. V. (2009) · Obesity and metabolism · doi:10.14341/2071-8713-5311

Clinical lipid management of patients with mild-to-moderate hypertriglyceridemia

Maki, K. C., Dicklin, M. R., & Bays, H. E. (2012) · Clinical Lipidology · doi:10.2217/clp.12.37

GENDER DIFFERENCES OF LIPID PROFILE IN TYPE 2 DIABETES MELLITUS

Chowta, M. N., Adhikari, P., Sivaraj, R., Chowta, N. K., Shenoy, A. K., Ramapuram, J., & Rao, S. B. (2012)

PREVENTIVE ACTION OF ORLISTAT ON CARDIOVASCULAR RISKS IN YOUNG OBESITY PATIENTS

Корнеева, Е. В. (2015) · CARDIOVASCULAR THERAPY AND PREVENTION · doi:10.15829/1728-8800-2015-4-38-43

A Prospective Study to Analyse the Metabolic Effect of Metformin with Glimepiride on Type 2 Diabetic Patients of North India

Singh, P., Khan, F. A., Hemnani, T., Matreja, P. S., & Singh, V. (2016) · Annals of International medical and Dental Research · doi:10.21276/aimdr.2016.2.4.59

The effect of orlistat on postprandial hypertriglyceridemia by oral fat loading test. A systematic review

Rodríguez-Valle, A., Ferrando, M. Á. N., Carceller, D. B., González-Cantalejo, M., Marcén, J. F. E., & Sanz‐París, A. (2016) · Nutrición Hospitalaria · doi:10.20960/nh.525

Usage of metformin in patients with type 2 diabetes mellitus

Huang, W. (2016) · UTAS Research Repository · doi:10.25959/23240615

Molecular and cellular targets in the management of metabolic diseases and disorders: An overview

Cariño‐Cortés, R., Isabel, S.-C. M., Antonio, E.-D. J., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00004-4

Pharmacological targets in metabolic syndrome related dyslipidemia

Cariño‐Cortés, R., Manuel, M.-P. V., Ortiz, M. I., Luis, J.-S., Fernández‐Martínez, E., & Fernanda, V.-C. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-27370-4.00005-6

Cholesterol transport by various lipoproteins

Bhale, A. S., & Venkataraman, K. (2025) · Elsevier eBooks · doi:10.1016/b978-0-443-19116-9.00018-x

The Effects of Medications Used for the Management of Dyslipidemia on Postprandial Lipemia

Tentolouris, N., Eleftheriadou, I., & Katsilambros, N. L. (2008) · Current Medicinal Chemistry · doi:10.2174/092986709787002763 · Cited by 12 · see citing works

Rosiglitazone Improves Postprandial Triglyceride and Free Fatty Acid Metabolism in Type 2 Diabetes

van Wijk, J. P. H., de Koning, E. J. P., Cabezas, M. C., & Rabelink, T. J. (2005) · Diabetes Care · doi:10.2337/diacare.28.4.844 · Cited by 82 · see citing works

Effect of acarbose on postprandial lipid metabolism in type 2 diabetes mellitus

Kado, S., Murakami, T., Aoki, A., Nagase, T., Katsura, Y., Noritake, M., Matsuoka, T., & Nagata, N. (1998) · Diabetes Research and Clinical Practice · doi:10.1016/s0168-8227(98)00062-x · Cited by 59 · see citing works

Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes

Lund, S. S., Tarnow, L., Frandsen, M., Smidt, U., Pedersen, O. B., Parving, H., & Vaag, A. A. (2008) · European Journal of Endocrinology · doi:10.1530/eje-07-0500 · Cited by 34 · see citing works

Gemfibrozil reduces postprandial lipemia in non-insulin-dependent diabetes mellitus.

MSyvänne, HVuorinen-Markkola, HHilden, & RTaskinen, M. (1993) · Arteriosclerosis and Thrombosis A Journal of Vascular Biology